Whole Body Vibration Therapy in Boys With Duchenne Muscular Dystrophy

NCT01954940 | Completed

• 1 other identifier: # 12/17E
• Study Type: interventional
• Target: 4
• Locations: 1 country
• Sites: 1

Brief Summary

Whole-body vibration therapy (WBVT) is a novel, non-pharmacological intervention aimed at improving muscle strength and endurance as well as bone density. It holds promise for children with neuromuscular disorders such as Duchenne muscular dystrophy (DMD) since muscle weakness results not only from muscle breakdown but also physical inactivity and muscle disuse atrophy. Weak DMD patients may increasingly limit their physical activity due to fear of falling or loss of independence (e.g. difficulty rising to stand without assistance). Prolonging the length of time boys with DMD are ambulatory is important for delaying complications of this disease (lung hypoventilation, scoliosis) as well as maintaining bone health. We propose to conduct a pilot study of WBVT in young boys with Duchenne muscular dystrophy (DMD). The primary outcome will be to document safety and feasibility of WBVT in this patient population. The secondary outcomes will evaluate changes in muscle strength and endurance. Bone health will also be examined as part of routine clinical care. The study will include 20 ambulatory boys with DMD; patients will be randomized (1:1 allocation) into 2 groups: WBVT treatment or no WBVT treatment (controls). Treatment groups will consist of 10 boys undergoing daily WBVT in an 8-week, open-label trial.

Conditions

Duchenne Muscular Dystrophy

Keywords

Whole body vibration therapy, muscle strength testing, bone health, ambulatory, endurance.

Outcome Measures

Primary Outcomes (1)

• Assess the safety of using whole body vibration therapy in boys with Duchenne muscular dystrophy. To assess whether whole body vibration therapy can improve muscle strength and prolong ambulation from baseline to 8 weeks of therapy. To asses.

  Is WBVT safe, convenient and well-tolerated when administered daily to ambulatory to boys with DMD?

  8 weeks

Secondary Outcomes (6)

• Does WBVT result in any change in muscle strength.

  8 weeks

• Does WBVT result in any muscle function change.

  8 weeks

• Does WBVT result in any measurable change in muscle endurance.

  8 weeks

• Quality of life changes.

  8 weeks

• Gait changes.

  8 weeks

Study Arms (2)

Whole Body Vibration Therapy

EXPERIMENTAL

Group will receive daily whole body vibration therapy for up to 9 minutes maximum at a maximum of 18 Hz.

Device: Whole Body Vibration Therapy

Control group

NO INTERVENTION

Group will not receive whole body vibration therapy. This group will conduct all other tests and outcomes except whole body vibration therapy.

Interventions

Whole Body Vibration Therapy DEVICE

Whole Body Vibration Therapy

Eligibility Criteria

• Age: 8 Years - 14 Years
• Sex: male
• Healthy Volunteers: No
• Age Groups: Child (0-17)

You may qualify if:

• Diagnosis of Duchenne muscular dystrophy confirmed by at least one of the following:
• Dystrophin immunofluorescence and/or immunoblot showing complete dystrophin deficiency, and clinical presentation consistent with typical DMD
• Positive gene deletion test (missing one or more exons) in the central rod domain (exons 25-60) of dystrophin, where reading frame can be predicted as "out-of-frame", and clinical presentation consistent with typical DMD
• Complete dystrophin gene sequencing showing an alteration (point mutation, duplication, or other mutation resulting in a stop codon mutation) definitively associated with DMD, and clinical presentation consistent with typical DMD
• Age between 5 - 14 yrs old (inclusive)
• Positive Gower sign (indicating ability to rise from the floor \& presence of proximal muscle weakness).
• Able to walk 10 meters in \<12 seconds
• Able to stand upon WBVT plate (with knees flexed) for entire treatment protocol (i.e. 15-minutes)
• Stable absolute dose of glucocorticoids (i.e. prednisone or deflazacort) for at least 3 months prior
• Stable absolute doses of all medication that may affect muscle function (i.e. coenzyme Q10, green tea extract, creatine, arginine, glutamine, nutritional supplements, etc.) for at least 3 months prior
• Stable absolute dose of all medication that may affect bone metabolism (i.e. vitamin D and calcium supplementation) for at least 3 months prior

You may not qualify if:

• Clinical presentation, genetic testing and/or muscle biopsy consistent with Becker muscular dystrophy
• History of recent surgery (within past 6-months)
• History of a recent fracture (long-bone or vertebral) within past 6-months.
• Acute inflammatory processes of lower extremities (e.g. cellulitis, etc) due to risk of pain and/or worsening inflammatory process
• History of venous thrombosis (theoretically risk of inducing thromboembolic event).
• History of kidney or bladder stones
• History of uncontrolled seizures or severe migraines
• History of cardiac arrhythmia
• Intracranial pathology or hardware (e.g. ventriculoperitoneal shunt, cochlear implant).
• Use of any investigational or experimental products within last 6-months and/or concomitant participation in another study
• Inability or refusal to follow the study requirements (e.g. autism, severe cognitive or behaviour problems)
• Inability or refusal to provide informed consent (parent) and/or assent (child)

Sponsors & Collaborators

• Children's Hospital of Eastern Ontario: lead

Study Sites (1)

Children's Hospital of Eastern Ontario

Ottawa, Ontario, K1H 8L1, Canada

Location

MeSH Terms

Conditions

Muscular Dystrophy, Duchenne

Condition Hierarchy (Ancestors)

Muscular Dystrophies; Muscular Disorders, Atrophic; Muscular Diseases; Musculoskeletal Diseases; Neuromuscular Diseases; Nervous System Diseases; Genetic Diseases, X-Linked; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Study Officials

• Leanne Ward, MD

  Children's Hospital of Eastern Ontario

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD

Study Record Dates

• First Submitted: September 13, 2013
• First Posted: October 7, 2013
• Study Start: March 1, 2013
• Primary Completion: March 1, 2017
• Study Completion: March 1, 2017
• Last Updated: August 31, 2018

Record last verified: 2018-08

Locations

CA (1)